#GMAB

Angry Gnat in TX

@texasbluedot70.bsky.social

1 month ago

Grieve? #GMAB

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

Why Are Investors Paying Attention To Genmab Stock? - Genmab (NASDAQ:GMAB) Shares of Genmab (NASDAQ: GMAB) are rising Wednesday after the Danish biotechnology company said it would partner with AI company Anthropic.

Why Are Investors Paying Attention To Genmab Stock? Shares of Genmab (NASDAQ: GMAB) are rising Wednesday after the Danish biotechnology company said it would partner with AI company Anthropic. read...

#GMAB #News #why #it's #moving #Movers #GMAB #News #Movers #Benzinga

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period Genmab A/S announced today that the conditions, including the minimum tender condition, to the previously announced tender offer by Genmab Holding II B.V., a wholly owned subsidiary of Genmab, to acquire all the issued and outstanding common shares of Merus N.V. for $97 per common share in cash have been satisfied. The transaction meaningfully accelerates...

#GMAB #MRUS Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

www.stocktitan.net/news/GMAB/genmab-announc...

0 0 0 0

InsiderFinance

@insiderfinance.com

3 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ERO, #NWG, #FLO, #BTU, #GMAB

#OptionFlow #OptionsTrading #Trading

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting Genmab (Nasdaq: GMAB) will present more than 20 abstracts, including seven oral presentations, on epcoritamab at the 67th ASH Annual Meeting, December 6-9, 2025.Highlights include primary Phase 3 EPCORE FL-1 results of epcoritamab plus rituximab and lenalidomide (R2) in relapsed or refractory follicular lymphoma, multiple oral sessions on first- and second-line use in follicular lymphoma and first-line use in diffuse large B-cell lymphoma (DLBCL), and long-term durability data (2–4+ year remissions) across trials. Genmab will host a virtual R&D Update and ASH data review on December 11, 2025.

#GMAB Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

www.stocktitan.net/news/GMAB/genmab-to-show...

0 0 0 0

Beachy Cat Lady

@clovercowgirl.bsky.social

4 months ago

tRump, and Republicans, care more about billionaires, who they give tax breaks to, and building gilded ballrooms to dance in, than they do for ANYONE affected by a shutdown. 🙏 #GMAB 🤡

0 0 1 0

Angry Gnat in TX

@texasbluedot70.bsky.social

4 months ago

Afraid of guys who can’t do 15 pushups, 32 sit-ups & run 1.5 miles in 14 minutes? #GMAB

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model Genmab (Nasdaq: GMAB) has announced its plans to acquire Merus (Nasdaq: MRUS) in an all-cash transaction valued at approximately USD 8.0 billion, or USD 97.00 per share. The acquisition represents a 41% premium over Merus' closing price on September 26, 2025.The strategic acquisition brings petosemtamab, a late-stage oncology asset with two FDA Breakthrough Therapy Designations for head and neck cancer, into Genmab's portfolio. The Phase 3 asset showed promising Phase 2 data at ASCO 2025, with superior overall response rates and progression-free survival compared to standard care. Genmab expects potential product launch in 2027, with projected annual sales of $1+ billion by 2029.The transaction will be funded through cash and $5.5 billion in non-convertible debt. Genmab aims to achieve gross leverage below 3x within two years post-closing. The deal is expected to close by early Q1 2026 and become EBITDA accretive by end of 2029.

#GMAB #MRUS Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

www.stocktitan.net/news/GMAB/genmab-to-acqu...

0 0 0 0

Michael

@rushstreetblues.bsky.social

5 months ago

What press? You mean the hand picked so-called press that is allowed into the press pool? That press? #GMAB

7 0 0 0

StockTitan

@stocktitan.net

6 months ago

FDA Grants Breakthrough Status to Genmab's Rina-S: New Hope for Advanced Endometrial Cancer Patients FDA grants Breakthrough Therapy Designation for Rina-S in recurrent endometrial cancer based on Phase 1/2 trial with 64 patients. Phase 3 trial planned.

#GMAB Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

www.stocktitan.net/news/GMAB/genmab-receive...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Genmab (NASDAQ: GMAB) announced positive results from its Phase 3 EPCORE® FL-1 trial for epcoritamab combined with rituximab and lenalidomide (R2) in treating relapsed/refractory follicular lymphoma. The trial met both primary endpoints with significant improvements in Overall Response Rate (95.7%, p<0.0001) and Progression-Free Survival (HR 0.21, p<0.0001), reducing disease progression risk by 79%.The FDA has accepted a priority review for the supplemental Biologics License Application (sBLA) with a target action date of November 30, 2025. If approved, this combination would become the first bispecific antibody regimen available as a second-line treatment for R/R FL patients. The safety profile aligned with known individual regimens with no new safety signals observed.

#GMAB Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

www.stocktitan.net/news/GMAB/genmab-announc...

0 0 0 0

BigPapaDilly

@bigpapadilly.bsky.social

8 months ago

And in the two and a half years while he was in office since then, Biden didn't do a DAMN THING to fix it. 😡 He could've added seats. He could've done lots of things. But he (and you) were too busy pretending this was all normal instead of catastrophic. But sure, NOW you want to complain. #GMAB

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

9 months ago

www.fool.com/investing/2025/06/02/why...

#GMAB #^GSPC #27c7f8c0-456f-4220-a080-18eaa0420e21 #investing

Result Details

0 0 0 0

kait

@kaitkroekel.bsky.social

9 months ago

#michaelclifford #waterparks #gmab #givemeabreaksong #5sos #digitaldrawing #procreatedrawing

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Breakthrough Cancer Data: Genmab Reveals First Rina-S Results for Deadly Endometrial Cancer at ASCO 2025 New Phase 1/2 trial results for Rina-S in endometrial cancer plus 3-year epcoritamab lymphoma data to be presented. Get exclusive insights from ASCO 2025.

#GMAB Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

www.stocktitan.net/news/GMAB/genmab-to-high...

0 0 0 0

Dolores A

@deejargon.bsky.social

11 months ago

She can’t recall a lot of info during her testimony. #GMAB 🤦🏼

11 0 1 1

StockTitan

@stocktitan.net

11 months ago

Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial Latest Phase 1/2 data reveals Genmab's Rina-S demonstrates strong efficacy with 88.9% disease control rate in advanced ovarian cancer patients. Complete responses observed in select cases.

#GMAB Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

www.stocktitan.net/news/GMAB/investigationa...

0 0 0 0

Axolotl_Here

@styledgirl.bsky.social

1 year ago

@southwest.com u think the ppl that made u profitable for 47yrs will pay for bags, seats, or more expensive tix (on old planes) @ a lower point rate…

Instead of signing up for competitors cc with free bags, elite perks, lounge access, & worldwide partner flights?! Come on.

#SouthwestAirlines #GMAB

2 0 0 0